355 related articles for article (PubMed ID: 17499324)
21. Arsenic toxicity at low doses: epidemiological and mode of action considerations.
Schoen A; Beck B; Sharma R; Dubé E
Toxicol Appl Pharmacol; 2004 Aug; 198(3):253-67. PubMed ID: 15276404
[TBL] [Abstract][Full Text] [Related]
22. Arsenic carcinogenesis in the skin.
Yu HS; Liao WT; Chai CY
J Biomed Sci; 2006 Sep; 13(5):657-66. PubMed ID: 16807664
[TBL] [Abstract][Full Text] [Related]
23. Appropriate use of animal models in the assessment of risk during prenatal development: an illustration using inorganic arsenic.
Holson JF; Desesso JM; Jacobson CF; Farr CH
Teratology; 2000 Jul; 62(1):51-71. PubMed ID: 10861633
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity of combinations of arsenicals on rat urinary bladder urothelial cells in vitro.
Nascimento MG; Suzuki S; Wei M; Tiwari A; Arnold LL; Lu X; Le XC; Cohen SM
Toxicology; 2008 Jul; 249(1):69-74. PubMed ID: 18502017
[TBL] [Abstract][Full Text] [Related]
25. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
26. Identification of interspecies concordance of mechanisms of arsenic-induced bladder cancer.
Sen B; Wolf DC; Turpaz Y; Bugrim A; Retief J; Hester SD
Toxicol In Vitro; 2007 Dec; 21(8):1513-29. PubMed ID: 17720352
[TBL] [Abstract][Full Text] [Related]
27. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis.
Mink PJ; Alexander DD; Barraj LM; Kelsh MA; Tsuji JS
Regul Toxicol Pharmacol; 2008 Dec; 52(3):299-310. PubMed ID: 18783726
[TBL] [Abstract][Full Text] [Related]
28. Carcinogen exposure and epigenetic silencing in bladder cancer.
Marsit CJ; Karagas MR; Schned A; Kelsey KT
Ann N Y Acad Sci; 2006 Sep; 1076():810-21. PubMed ID: 17119258
[TBL] [Abstract][Full Text] [Related]
29. A physiologically based pharmacokinetic model of inorganic arsenic.
Yu D
Regul Toxicol Pharmacol; 1999 Apr; 29(2 Pt 1):128-41. PubMed ID: 10341143
[TBL] [Abstract][Full Text] [Related]
30. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
31. Effects of co-administration of dietary sodium arsenite and an NADPH oxidase inhibitor on the rat bladder epithelium.
Suzuki S; Arnold LL; Pennington KL; Kakiuchi-Kiyota S; Cohen SM
Toxicology; 2009 Jun; 261(1-2):41-6. PubMed ID: 19397947
[TBL] [Abstract][Full Text] [Related]
32. Arsenic cancer risk posed to human health from tilapia consumption in Taiwan.
Liao CM; Shen HH; Lin TL; Chen SC; Chen CL; Hsu LI; Chen CJ
Ecotoxicol Environ Saf; 2008 May; 70(1):27-37. PubMed ID: 18068227
[TBL] [Abstract][Full Text] [Related]
33. Analysis of in vivo mutation data can inform cancer risk assessment.
Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
[TBL] [Abstract][Full Text] [Related]
34. Workshop overview: arsenic research and risk assessment.
Sams R; Wolf DC; Ramasamy S; Ohanian E; Chen J; Lowit A
Toxicol Appl Pharmacol; 2007 Aug; 222(3):245-51. PubMed ID: 17336359
[TBL] [Abstract][Full Text] [Related]
35. A Weibull-PBPK model for assessing risk of arsenic-induced skin lesions in children.
Liao CM; Lin TL; Chen SC
Sci Total Environ; 2008 Mar; 392(2-3):203-17. PubMed ID: 18207220
[TBL] [Abstract][Full Text] [Related]
36. The impact of recent advances in research on arsenic cancer risk assessment.
Gentry PR; Clewell HJ; Greene TB; Franzen AC; Yager JW
Regul Toxicol Pharmacol; 2014 Jun; 69(1):91-104. PubMed ID: 24534001
[TBL] [Abstract][Full Text] [Related]
37. Understanding arsenic carcinogenicity by the use of animal models.
Wanibuchi H; Salim EI; Kinoshita A; Shen J; Wei M; Morimura K; Yoshida K; Kuroda K; Endo G; Fukushima S
Toxicol Appl Pharmacol; 2004 Aug; 198(3):366-76. PubMed ID: 15276416
[TBL] [Abstract][Full Text] [Related]
38. Elevation of 8-hydroxydeoxyguanosine and cell proliferation via generation of oxidative stress by organic arsenicals contributes to their carcinogenicity in the rat liver and bladder.
Kinoshita A; Wanibuchi H; Wei M; Yunoki T; Fukushima S
Toxicol Appl Pharmacol; 2007 Jun; 221(3):295-305. PubMed ID: 17481689
[TBL] [Abstract][Full Text] [Related]
39. Trichloroethylene and cancer: epidemiologic evidence.
Scott CS; Cogliano VJ
Environ Health Perspect; 2000 May; 108 Suppl 2():159-60. PubMed ID: 10807549
[TBL] [Abstract][Full Text] [Related]
40. Animal models for arsenic carcinogenesis: inorganic arsenic is a transplacental carcinogen in mice.
Waalkes MP; Liu J; Ward JM; Diwan BA
Toxicol Appl Pharmacol; 2004 Aug; 198(3):377-84. PubMed ID: 15276417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
